Home/Filings/4/0001225208-24-005706
4//SEC Filing

Szyman Catherine M. 4

Accession 0001225208-24-005706

CIK 0001099800other

Filed

May 5, 8:00 PM ET

Accepted

May 6, 7:18 PM ET

Size

10.3 KB

Accession

0001225208-24-005706

Insider Transaction Report

Form 4
Period: 2024-05-03
Szyman Catherine M
CVP, Critical Care & Vascular
Transactions
  • Tax Payment

    Common Stock

    2024-05-04$85.25/sh3,442$293,43145,576.437 total
  • Tax Payment

    Common Stock

    2024-05-03$85.06/sh479$40,74443,222.437 total
  • Exercise/Conversion

    Common Stock

    2024-05-04+5,79649,018.437 total
  • Exercise/Conversion

    Performance Rights

    2024-05-045,7960 total
    From: 2024-05-04Exp: 2028-05-03Common Stock (5,796 underlying)
Footnotes (1)
  • [F1]On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

Documents

1 file

Issuer

Edwards Lifesciences Corp

CIK 0001099800

Entity typeother

Related Parties

1
  • filerCIK 0001438538

Filing Metadata

Form type
4
Filed
May 5, 8:00 PM ET
Accepted
May 6, 7:18 PM ET
Size
10.3 KB